osine-enhanced ischemic preconditioning: adenosine receptor involvement during ischemia and reperfusion. Am J Physiol Heart Circ Physiol 280: H591-H602, 2001.-Adenosineenhanced ischemic preconditioning (APC) extends the cardioprotection of ischemic preconditioning (IPC) by both significantly decreasing myocardial infarct size and significantly enhancing postischemic functional recovery. In this study, the role of adenosine receptors during ischemia-reperfusion was determined. Rabbit hearts (n ϭ 92) were used for Langendorff perfusion. Control hearts were perfused for 180 min, global ischemia hearts received 30-min ischemia and 120-min reperfusion, and IPC hearts received 5-min ischemia and 5-min reperfusion before ischemia. APC hearts received a bolus injection of adenosine coincident with IPC. Adenosine receptor (A 1 , A 2 , and A 3 ) antagonists were used with APC before ischemia and/or during reperfusion. GR-69019X (A 1 / A 3 ) and MRS-1191/MRS-1220 (A 3 ) significantly increased infarct size in APC hearts when administered before ischemia and significantly decreased functional recovery when administered during both ischemia and reperfusion (P Ͻ 0.05 vs. APC). DPCPX (A 1 ) administered either before ischemia and/or during reperfusion had no effect on APC cardioprotection. APC-enhanced infarct size reduction is modulated by adenosine receptors primarily during ischemia, whereas APC-enhanced postischemic functional recovery is modulated by adenosine receptors during both ischemia and reperfusion. adenosine receptors; infarct size PREVIOUSLY we (16-18, 25) reported a novel myocardial protective protocol we have termed adenosine-enhanced ischemic preconditioning (APC), in which a bolus injection of adenosine is used coincident with single-cycle ischemic preconditioning (IPC). In a series of reports, we (16) (17) (18) 25) have shown that APC extends the cardioprotection afforded by IPC by significantly decreasing myocardial infarct size (P Ͻ 0.05 vs. IPC) and significantly enhancing postischemic functional recovery (P Ͻ 0.05 vs. IPC) in isolated perfused rabbit hearts and in in situ blood-perfused sheep hearts.
PREVIOUSLY we (16) (17) (18) 25) reported a novel myocardial protective protocol we have termed adenosine-enhanced ischemic preconditioning (APC), in which a bolus injection of adenosine is used coincident with single-cycle ischemic preconditioning (IPC). In a series of reports, we (16) (17) (18) 25) have shown that APC extends the cardioprotection afforded by IPC by significantly decreasing myocardial infarct size (P Ͻ 0.05 vs. IPC) and significantly enhancing postischemic functional recovery (P Ͻ 0.05 vs. IPC) in isolated perfused rabbit hearts and in in situ blood-perfused sheep hearts.
Recently, we (23) have shown that APC infarct size reduction is modulated by ATP-sensitive K ϩ (K ATP ) channels primarily during ischemia and that postischemic functional recovery is modulated by K ATP channels during ischemia and reperfusion. The mechanism by which APC confers cardioprotection remains to be fully elucidated; however, in previous investigations by others (5, 6, 11, 12) , it has been shown that adenosine receptors are activated before the activation of K ATP channels and play a central role in mediating cardioprotection. The involvement of adenosine receptors in APC cardioprotection and the relevance and specificity of these receptors during ischemia and reperfusion were unknown. The purpose of this study was threefold: first; to confirm that the effects of adenosine when used as a bolus coincident with IPC (APC) were conferred before ischemia; second, to determine whether the cardioprotection afforded by APC was modulated by adenosine receptors and to determine whether this modulation occurred during ischemia or during reperfusion; and third, to determine the specificity of adenosine receptor modulation on APC cardioprotection during ischemia and reperfusion.
In this report, we show that APC cardioprotection is conferred by a bolus injection of adenosine coincident with IPC before ischemia. We also show that APC cardioprotection is modulated by adenosine receptors. Our results indicate that APC significantly enhanced myocardial infarct size reduction (P Ͻ 0.05 vs. IPC) is modulated by adenosine receptors primarily during ischemia, whereas APC significantly enhanced postischemic functional recovery (P Ͻ 0.05 vs. IPC) is modulated by adenosine receptors during ischemia and reperfusion.
METHODS

Animals and chemicals.
New Zealand White rabbits (n ϭ 92, 15-20 wk) were obtained from Millbrook Farm (Amherst, MA). All animals were housed individually and provided with laboratory chow and water ab libitum. All experiments were approved by the Beth Israel Deaconess Medical Center Animal Care and Use Committee and conformed to the United States National Institutes of Health guidelines regulating the care and use of laboratory animals (NIH publication 1996) .
Langendorff perfusion. Rabbits were anesthetized with pentobarbital sodium (Veterinary Laboratories, Lenexa, KA; 100 mg/kg) and heparin (200 U/kg) via the marginal ear vein. The aorta was cannulated, and the heart was subjected to Langendorff retrograde perfusion at a constant pressure of 75 cmH 2 O (at 37°C) (17, 18) . Hearts were paced via the right atrium at 180 Ϯ 3 beats/min throughout the experiment using a Medtronic stimulator (Medtronic, Minneapolis, MN). Hemodynamic variables were acquired continuously using the PO-NE-MAH digital data acquisition system (Gould, Valley View, OH) with an Acquire Plus processor board and left ventricular pressure analysis software.
Experimental protocol. Hearts were perfused for 20 min to establish equilibrium hemodynamics. Equilibrium was ceased when heart rate (HR), coronary flow (CF), and left ventricular peak developed pressure (LVPDP) and end-diastolic pressure (LVEDP) were maintained at the same level for three continuous measurement periods timed 5 min apart. Control hearts (n ϭ 8) were perfused without global ischemia (GI) for 180 min. GI hearts (n ϭ 8) were subjected to 30-min GI and 120-min reperfusion. GI was achieved by cross-clamping the aorta. IPC hearts (n ϭ 8) received 5-min zero-flow GI followed by 5-min reperfusion before 30-min GI and 120-min reperfusion. Single-cycle IPC was used based on previous results indicating enhanced cardioprotection compared with three cycles (25) . APC hearts (n ϭ 8) received a 10-ml bolus injection of adenosine (1 mmol/l) dissolved in Krebs buffer (Adenoscan; Medico, Research Triangle Park, NC) coincident with IPC (5-min zero-flow GI followed by 5-min reperfusion) (17, 18) . The bolus was injected into the aortic root via the side arm of a cannula located proximal to the perfusion cannula. To determine whether the cardioprotection afforded by APC occurred during ischemia or during reperfusion, a separate group of hearts (IPCϩADO, n ϭ 6) received IPC (5-min zero-flow GI followed by 5-min reperfusion) before ischemia followed by a 10-ml bolus injection of adenosine (1 mmol/l) after 30-min GI and just before reperfusion. Control, GI, and IPC hearts received a 10-ml bolus injection of Krebs buffer (17, 18) .
Role of adenosine receptors in APC cardioprotection during ischemia and reperfusion. To determine whether the cardioprotection afforded by APC was modulated by adenosine receptors and to determine the specificity of adenosine receptor modulation on APC cardioprotection during ischemia and/or during reperfusion, APC hearts were perfused separately with adenosine receptor (A 1 , A 2 , and A 3 ) antagonists. The adenosine receptor antagonists used in this study were 8-(p-sulfophenyl) theophylline (SPT, 100 mol/l; a nonselective A 1 /A 2 /A 3 adenosine receptor antagonist; Research Biochemicals, Natick, MA); 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 200 nmol/l; a selective A 1 receptor antagonist; Research Biochemicals); 8(4-carboxyethenylphenyl) xanthine [GR-69019X, 5 mol/l; an A 1 and A 3 receptor antagonist (24) , formerly known as BWA-1433, the kind gift of Glaxo Wellcome, Research Triangle Park, NC]; 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(Ϯ)-dihydropyridine-3,5-dicarboxylate (MRS-1191; an A 3 antagonist, selective for both human and rat A 3 receptors); and 9-chloro-2-(2-furanyl)-5-[(phenylacetyl)amino]-(1,2,4)-triazolo(1,5-c)-quinazoline [MRS-1220 (MRS), 500 nmol/l; an A 3 antagonist with greater selectivity for human compared with rat A 3 receptors; Research Biochemicals] (7, 8, 14, 21) .
The concentration of SPT (A 1 /A 2 /A 3 ) used in these experiments was derived from the previous investigation of Hendrikx et al. (9) . The concentration of DPCPX (A 1 ) used in these experiments was derived from previous investigation by others (1, 14) . The concentration of GR-69019X used for (A 1 /A 3 ) was derived from a previous investigation by Tracey et al. (24) .
Stock solutions of adenosine receptor antagonists were prepared separately and then diluted to appropriate concentration in Krebs-Ringer solution equilibrated with 95% O 2 -5% CO 2 (pH 7.4 at 37°C). MRS-1191, MRS-1220, and GR-69019X were dissolved in DMSO, SPT was dissolved in Krebs buffer, and DPCPX was dissolved in ethanol. Control hearts were pretreated with a placebo injection of 10 ml of Krebs buffer containing an appropriate amount of DMSO (final concentration Ͻ 0.1%). Adenosine receptor antagonist protocols were randomly assigned.
To determine the effect of adenosine receptors in APC cardioprotection during ischemia, APC hearts received, separately, adenosine receptors antagonists for 5 min before APC and for the first 2 min during the short 5-min reperfusion before GI ( Fig. 1 ; SPT, DPCPX, GR-69019X, and MRS: n ϭ 6 each group). The effect of adenosine receptors in APC cardioprotection during reperfusion was determined by separate adenosine receptor antagonist administration to APC hearts for 2 min at the start of reperfusion after 30-min GI [60-62 min of perfusion; Fig. 1 ; SPT at start of reperfusion (-R), DPCPX-R, GR-69019X-R, and MRS-R: n ϭ 6 each group]. In GR-69019X studies, an additional experimental group of APC hearts received GR-69019X (5 mol/l) for 5 min Fig. 1 . Experimental protocol used for the investigation of adenosine receptors in adenosine-enhanced ischemic preconditioning (APC) during ischemia and reperfusion. APC hearts were perfused separately with the following: 1) the A 1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine before global ischemia (GI) (DPCPX) or at the start of reperfusion (DPCPX-R); 2) the adenosine A 1 /A 3 receptor antagonist GR-69019X before GI (GR-69019X) or at the start of reperfusion (GR-69019X-R) or both before ischemia and at the start of reperfusion (GR-69019X I-R); 3) the adenosine receptor antagonists MRS-1191 and MRS-1220 (A 3 ) before GI (MRS) or at the start of reperfusion (MRS-R); and 4) the nonselective adenosine receptor antagonist 8-(p-sulfophenyl) theophylline (A 1 /A 2 /A 3 ) before GI (SPT) or at the start of reperfusion (SPT-R). To determine the effect of adenosine receptors in APC cardioprotection during ischemia, APC hearts received, separately, adenosine receptor antagonists for 5 min before APC and for the first 2 min during the short 5-min reperfusion before GI. The effect of adenosine receptors in APC cardioprotection during reperfusion was determined by separate adenosine receptor antagonist infusion in APC hearts for 2 min at the start of reperfusion after 30-min GI (60-to 62-min perfusion). In GR-69019XI-R studies, APC hearts received GR-69019X (5 mol/l) for 5 min before APC and for the first 2 min during the short 5-min reperfusion before GI and for 2 min at the start of reperfusion after 30-min GI (60-to 62-min perfusion).
before APC, for the first 2 min during the short 5-min reperfusion before GI, and for 2 min at the start of reperfusion after 30-min GI ( Fig. 1 ; GR-69019X I-R: n ϭ 6).
Adenosine receptor antagonists in all experiments were perfused for 5 min just before APC and for the first 2 min during the short 5-min reperfusion before GI based on initial experiments, which indicated that the use of adenosine receptor antagonists only before APC had variable effects on the cardioprotection afforded by APC. We speculate that these results were caused by the bolus injection of adenosine that competitively inhibited the action of the adenosine receptor antagonists.
Measurement of infarct size. Infarct size was determined as previously described (17, 18) . Infarct size was expressed as a percentage of left ventricular volume for each heart. Wet-todry weight ratios were determined as previously described (17, 18) .
Statistical analysis. Statistical analysis was performed using SAS (version 6.12) software package (SAS Institute, Cary, NC). The means Ϯ SE for all data were calculated for all variables. Statistical significance was determined using repeated measures analysis of variance with group as a between-subjects factor and time as a within-subjects factor. Post hoc comparisons between groups for both the average effect and at individual time points were made using a Tukey correction to adjust for the multiplicity of tests. A one-way analysis of variance was used for area of infarction.
RESULTS
Role of adenosine in APC cardioprotection during ischemia and reperfusion. No significant differences in HR, LVEDP, LVPDP, the positive first derivative of pressure over time (ϩdP/dt), or CF were observed between or within groups after equilibrium (15-min perfusion; Fig. 2 and Table 1 ). LVPDP in IPC, APC, and IPCϩADO hearts decreased to 0 mmHg during IPC (25-min perfusion) and then returned to control level during the short reperfusion period before the induction of GI (30-min perfusion; Fig. 2 ). No significant difference from equilibrium was observed between groups before GI. A delayed recovery of LVPDP was observed in all groups during the first 20 min of reperfusion (60-to 80-min perfusion; Fig. 2 ). After 20 min of reperfusion (80-min perfusion), no significant difference between APC and control hearts was observed. LVPDP in GI, IPC, and IPCϩADO was significantly decreased (P Ͻ 0.05) compared with control hearts throughout reperfusion and was significantly decreased (P Ͻ 0.05) compared with APC hearts after 30-min reperfusion (90-to 180-min perfusion). LVEDP was significantly increased in GI, IPC, and IPCϩADO hearts (P Ͻ 0.05 vs. APC) throughout reperfusion. Similar results were observed for maximum ϩdP/dt ( Table 1) .
CF gradually decreased throughout reperfusion (60-to 180-min perfusion) in GI, IPC, and IPCϩADO hearts and was significantly decreased (P Ͻ 0.05) in these groups compared with APC and control hearts by 120 min of reperfusion (180-min perfusion) ( Table 1) .
Infarct size was significantly increased (P Ͻ 0.001) in GI hearts (31.2 Ϯ 4.0%) compared with control hearts (0.8 Ϯ 0.3%) after 30-min normothermic GI and 120-min reperfusion (Fig. 3 ). Infarct size in IPC (13.9 Ϯ 1.3%) and IPCϩADO (12.8 Ϯ 0.6%) was significantly decreased (P Ͻ 0.001 each) compared with GI hearts but was significantly increased (P Ͻ 0.01) compared with control and APC hearts. No significant difference in infarct size was observed between control and APC (2.8 Ϯ 0.4%) hearts (Fig. 3) . No significant differences in wet-to-dry weight ratios were found between any groups (results not shown).
These data indicate that the enhanced cardioprotection afforded by APC [significantly decreased infarct size and significantly enhanced postischemic functional recovery (P Ͻ 0.05 vs. ADO, IPC)] occurs through the additive actions of a bolus injection of adenosine acting in synergy with IPC before ischemia Fig. 2 . Left ventricular peak developed pressure (LVPDP; in mmHg) during equilibrium, GI (30-to 60-min perfusion) and reperfusion (60-to 180-min perfusion) in control, GI, ischemic preconditioning (IPC), APC, and IPCϩADO hearts. IPC hearts received 5 min zero-flow GI followed by 5-min reperfusion before 30-min GI and 120-min reperfusion, shown by bars at 25-to 30-min perfusion. APC hearts received a 10-mL bolus injection of adenosine (1 mmol/l) dissolved in Krebs buffer coincident with IPC (5-min zero-flow GI followed by 5-min reperfusion, shown by bars at 25-to 30-min perfusion). IPCϩADO hearts received IPC (5-min zeroflow GI followed by 5-min reperfusion) before ischemia followed by a 10-ml bolus injection of adenosine (1 mmol/l) after 30-min GI (60-min perfusion) and just before reperfusion. GI hearts received 30-min GI and 120-min reperfusion. Control hearts did not received GI and were perfused for 180 min. Results are shown as the mean Ϯ SE for n ϭ 6-8 hearts for each group. #Significant differences at P Ͻ 0.05 vs. control hearts. *Significant differences at P Ͻ 0.05 vs. APC hearts.
to extend the cardioprotection of adenosine and IPC. IPC followed by a bolus injection of adenosine delivered at the start of reperfusion (IPCϩADO) decreases myocardial infarct size, but this decrease in infarct size is significantly less (P Ͻ 0.05) than that achieved with APC, and there is no enhancement of postischemic functional recovery.
Role of adenosine receptors in APC cardioprotection during ischemia and reperfusion. LVPDP in SPT and SPT-R hearts was significantly decreased (P Ͻ 0.05) compared with APC hearts throughout reperfusion (60-to 180-min perfusion; Fig. 4 ). LVEDP in SPT hearts was significantly increased (P Ͻ 0.05 vs. APC) throughout reperfusion (60-to 180-min perfusion), whereas LVEDP in SPT-R was significantly increased (P Ͻ 0.05 vs. APC) at 60-to 120-min reperfusion (120-to 180-min perfusion; Table 2 ). LVEDP was significantly increased in SPT hearts compared with SPT-R hearts throughout reperfusion. Similar findings were observed for maximum ϩdP/dt (Table 2) . CF was significantly decreased in SPT and SPT-R hearts throughout reperfusion (P Ͻ 0.05 vs. APC; Table 2 ).
Infarct size in SPT hearts was significantly increased to 26.7 Ϯ 4.1% compared with APC and SPT-R hearts [P Ͻ 0.001 and P Ͻ 0.01, respectively, not significant (NS) vs. GI; Fig. 8 ]. Infarct size in SPT-R hearts was 13.6 Ϯ 1.0% significantly increased (P Ͻ 0.01) compared with APC hearts (Fig. 8) . There was no significant difference in infarct size between SPT and GI hearts or SPT-R and IPC hearts (Fig. 8) . No significant differences in wet-to-dry weight ratios were found between any groups (results not shown).
These data indicate that the enhanced cardioprotection afforded by APC [significantly decreased infarct size and significantly enhanced postischemic func- Fig. 3 . Infarct size after 30-min GI and 120-min reperfusion in control, GI, IPC, APC, and IPCϩADO hearts. Results are shown as the mean Ϯ SE for n ϭ 6-8 hearts for each group. #Significant differences at P Ͻ 0.05 vs. control hearts. *Significant differences at P Ͻ 0.05 vs. APC hearts. **Significant differences at P Ͻ 0.05 vs. IPC and IPCϩADO hearts. There were no significant differences in infarct size between APC and control hearts. These results indicate that APC significantly decreased myocardial infarct size occurs primarily during ischemia, whereas APC significantly enhanced postischemic functional recovery occurs during both ischemia and reperfusion.
Role of specific adenosine receptors in APC cardioprotection during ischemia and reperfusion. No significant differences in LVPDP or LVEDP compared with APC were observed between groups before the start of GI. During the first 10-min reperfusion (60-to 70-min perfusion), LVPDP in APC hearts in which DPCPX (A 1 ) was administered either before ischemia (DPCPX) or during reperfusion (DPCPX-R) was significantly decreased (P Ͻ 0.05 vs. APC), but by 20-min reperfusion (80-min perfusion) no significant differences between APC, DPCPX, DPCPX-R, and control hearts were observed ( Fig. 5 and Table 3) . LVPDP in APC hearts in which GR-69019X (A 1 /A 3 ) was administered before ischemia was significantly decreased (P Ͻ 0.05 vs. APC) throughout reperfusion (Fig. 6) . In contrast, in APC hearts in which GR-69019X (A 1 /A 3 ) was administered during reperfusion (GR-69019X-R), LVPDP was significantly decreased (P Ͻ 0.05 vs. APC) only during the first 30-min of reperfusion (Fig. 6) . LVPDP was significantly decreased (P Ͻ 0.05 vs. APC) throughout reperfusion in APC hearts in which GR-69019X (A 1 /A 3 ) was administered both before ischemia and during reperfusion (GR-69019X I-R; Fig. 6 ). Similar results were observed for maximum ϩdP/dt (Table 3) .
LVPDP in APC hearts in which MRS (A 3 ) was administered either before ischemia (MRS) or during reperfusion (MRS-R) was significantly decreased throughout reperfusion (60-to 180-min perfusion; P Ͻ 0.05 vs. APC) (Fig. 7) . Similar results were observed for maximum ϩdP/dt (Table 3) .
LVEDP was significantly increased in MRS, MRS-R, and GR-69019X I-R hearts throughout reperfusion (P Ͻ 0.05 vs. APC). LVEDP in DPCPX, DPCPX-R, GR-69019X, and GR-69019X-R hearts during reperfusion was not significantly different from APC hearts (Table 3) . CF was significantly decreased in GR-69019X I-R, MRS, and MRS-R hearts during reperfusion (P Ͻ 0.05 vs. APC; Table 3) . No significant differences in infarct size between control, APC, DPCPX (4.2 Ϯ 0.9%), or DPCPX-R (4.4 Ϯ 1.0%) hearts were observed (Fig. 8) .
Infarct size in APC hearts in which GR-69019X was administered before ischemia was 24.7 Ϯ 1.2% (P Ͻ 0.05 vs. control, APC, DPCPX, and DPCPX-R) and 8.5 Ϯ 1.5% in APC hearts in which GR-69019X was administered during reperfusion (P Ͻ 0.01 vs. GR-69019X) (Fig. 8) . Infarct size in APC hearts in which GR-69019X was administered both before ischemia and during reperfusion was 29.4 Ϯ 1.6% (P Ͻ 0.05 vs. control, APC, DPCPX, DPCPX-R, and GR-69019X-R; Fig. 8 ).
Infarct size in APC hearts in which MRS was administered before ischemia was 30.5 Ϯ 3.6% (P Ͻ 0.05 vs. control, APC, DPCPX, DPCPX-R, GR-69019X-R, and MRS-R) and 15.6 Ϯ 3.5% in APC hearts in which MRS was administered during reperfusion (P Ͻ 0.05 vs. control, APC, DPCPX , DPCPX-R, GR-69019X, and MRS; Fig. 8 ). No significant differences in wet-to-dry weight ratios were found among any groups (results not shown). Fig. 4 . LVPDP (in mmHg) during equilibrium, GI (30-to 60-min perfusion), and reperfusion (60-to 180-min perfusion) in GI, APC, and APC hearts perfused separately with the nonselective adenosine receptor antagonist SPT (A 1 /A 2 /A 3 ) before GI or at the start of reperfusion. All results are shown as the mean Ϯ SE for n ϭ 6 hearts for each group. *Significant differences at P Ͻ 0.05 vs. APC.
These data indicate that the enhanced cardioprotection afforded by APC [significantly decreased infarct size and significantly enhanced postischemic functional recovery (P Ͻ 0.05 vs. ADO and IPC)] is not affected by the A 1 receptor antagonist DPCPX either before ischemia or at the start of reperfusion. In contrast, APC infarct size reduction is completely abolished with GR-69019X (5 M; A 1 /A 3 ) or MRS (A 3 ) during ischemia and partially abolished with GR-69019X (5 M; A 1 /A 3 ) or MRS during reperfusion. These data further indicate that APC-enhanced postischemic functional recovery is modulated by GR-69019X (5 M; A 1 /A 3 ) or MRS (A 3 ) both during ischemia and reperfusion.
DISCUSSION
Previously, we (16-18, 22, 23, 25) reported that APC significantly decreases infarct size (P Ͻ 0.05 vs. adenosine only and IPC). We (16-18, 22, 23, 25) have also shown that APC significantly enhances postischemic functional recovery (P Ͻ 0.05 vs. adenosine only and IPC). Neither adenosine nor IPC enhanced postischemic functional recovery (16-18, 22, 23, 25) . Recently, we (23) reported that APC infarct size reduction is modulated by K ATP channels primarily during ischemia and that functional recovery is modulated by K ATP channels during ischemia and reperfusion. The mechanism by which APC confers cardioprotection remains to be fully elucidated; however, in previous investigations by others (5, 6, 11, 12) , it has been shown that adenosine receptors (A 1 or A 3 ) are activated before the activation of K ATP channels and play a central role in mediating cardioprotection. In the present study, we have investigated the role of adenosine receptors in the mechanism(s) leading to enhanced infarct size reduction and enhanced postischemic functional recovery in APC cardioprotection. Our data indicate that the enhanced cardioprotection afforded by APC occurs through the use of a bolus injection of adenosine coincident with IPC before ischemia (Figs. 2 and 3 and Table 1 ). IPC followed by a bolus injection of adenosine delivered at the start of reperfusion (IPCϩADO) decreased myocardial infarct size, but this decrease in infarct size was significantly less (P Ͻ 0.05) than that achieved with APC, and there was no enhancement of postischemic functional recovery, in agreement with our previous reports (16-18, 22, 23, 25) . These data support our earlier hypothesis that APC cardioprotection occurs via the additive actions of a bolus injection of adenosine acting in synergy with IPC to extend the cardioprotection of adenosine and IPC (16-18, 22, 23, 25) . It is important to note that only when adenosine was used coincident with IPC did enhanced postischemic functional recovery occur.
Previously, we (16) (17) (18) 25) have speculated that APC cardioprotection was associated with adenosine receptor activation. This speculation was based on earlier observations by others (12, 19) who suggested that adenosine acted as both a mediator and a trigger for preconditioning and that continued occupancy of aden- Table 2 . Hemodynamic data Table 2 , in which the nonspecific adenosine receptor antagonist SPT (A 1 /A 2 /A 3 ) was administered either before ischemia or during reperfusion, indicate that APC cardioprotection is modulated by adenosine receptors both before ischemia and during reperfusion. The administration of the nonspecific adenosine receptor antagonist SPT before ischemia completely abolished the effects of APC, with infarct size and postischemic functional recovery being similar to that observed in GI hearts, whereas the administration of SPT at the start of reperfusion abolished APC-enhanced postischemic functional recovery but only compromised APC myocardial infarct size reduction. Infarct size in SPT at the start of reperfusion was significantly increased (P Ͻ 0.05) compared with APC but not significantly different from that observed with IPC (Fig. 8) . These results are in agreement with our previous observations (23) and indicate that the significantly decreased myocardial infarct size achieved by APC occurs primarily during ischemia, whereas significantly enhanced postischemic functional recovery occurs during both ischemia and reperfusion.
Previous investigations by others (5, 6, 10, 15) suggest that two adenosine receptor subtypes, the adenosine A 1 and A 3 receptors, may be involved in the cardioprotection afforded by preconditioning in the rabbit heart. Our results shown in Figs. 5 and 8 and Table 3 indicate that administration of the A 1 receptor antagonist DPCPX either before ischemia or at the start of reperfusion had no effect on APC-enhanced infarct size reduction or APC-enhanced postischemic functional recovery. In contrast, as shown in Fig. 6 and Table 3 , administration of GR-69019X (5 M; A 1 /A 3, ) to APC hearts before ischemia significantly decreased APCenhanced postischemic functional recovery (LVPDP and ϩdP/dt) throughout reperfusion (P Ͻ 0.05 vs. APC, DPCPX, and DPCPX-R) and completely abolished APC-enhanced infarct size reduction (P Ͻ 0.05 vs. APC, NS vs. GI; Fig. 8 ). The administration of GR-69019X (5 M; A 1 /A 3 ) to APC hearts during reperfusion significantly decreased LVPDP during early reperfusion (60-to 90-min perfusion); however, no significant differences compared with APC hearts were observed at 120-to 180-min perfusion (Fig. 6) . When the adenosine receptor antagonist GR-69019X (5 M; A 1 /A 3 ) was administered to APC hearts both before ischemia and during reperfusion, LVPDP was significantly decreased throughout reperfusion (P Ͻ 0.05 vs. APC; Fig. 6) .
Similarly, the administration of MRS (MRS-1191 and MRS-1220) to APC hearts before ischemia completely abolished the effects of APC, with infarct size (Fig. 8) and postischemic functional recovery (LVPDP and ϩdP/dt; P Ͻ 0.05 vs. APC; Fig. 7 and Table 3 ) being similar to those observed in GI hearts. It is important to note that, whereas the administration of MRS to APC hearts at the start of reperfusion significantly decreased APC postischemic functional recovery (LVPDP and ϩdP/dt; P Ͻ 0.05 vs. APC; Fig. 7 and Table 3 ), infarct size in MRS hearts at the start of reperfusion was significantly increased (P Ͻ 0.05) compared with APC but was not significantly different from that observed with IPC (Fig. 8) . These results are similar to that observed in APC hearts in which the adenosine receptor antagonist SPT was administered to APC hearts either before ischemia or during reperfusion and add further support to our findings that the significantly decreased myocardial infarct size achieved by APC occurs primarily during ischemia, whereas significantly enhanced postischemic functional recovery occurs during both ischemia and reperfusion (23). 5 . LVPDP (in mmHg) during equilibrium, GI (30-to 60-min perfusion), and reperfusion (60-to 180-min perfusion) in GI, APC, and APC hearts perfused separately with the A 1 receptor antagonist DPCPX before GI or at the start of reperfusion. All results are shown as the mean Ϯ SE for n ϭ 6 hearts for each group. *Significant differences at P Ͻ 0.05 vs. APC. Table 3 . Hemodynamic data There is controversy as to the specificity and selectivity of adenosine receptor antagonists and the differences observed in postischemic functional recovery in APC hearts in which SPT or MRS compared with GR-69019X was administered during reperfusion may be related to the specificity and/or the selectivity of the antagonists used. In these investigations, we have used SPT, DPCPX, GR-69019X, and MRS-1191/MRS-1220 at previously reported concentrations that putatively allow for the selective antagonism of adenosine A 1 and/or A 3 receptors (1, 7, 8, 15, 24) . Previous reports (1, 9, 10, 15) have indicated that SPT is a nonselective antagonist (A 1 /A 2 /A 3 ) that blocks all adenosine receptor subtypes in the rabbit heart, whereas DPCPX is selective for A 1 receptors in the rabbit myocardium. Hill et al. (10) reported that the inhibitory constants (K i values) for the inhibition of The role of A 1 receptors in delayed or "second window" preconditioning has been previously reported, but the role of these receptors in early preconditioning remains controversial (3, 4, 20) . Downey et al. (6) initially reported that DPCPX failed to block the protection afforded by IPC in the rabbit heart. Further Fig. 6 . LVPDP (in mmHg) during equilibrium, GI (30-to 60-min perfusion), and reperfusion (60-to 180-min perfusion) in GI, APC, and APC hearts perfused separately with the adenosine receptor antagonist GR-69019X (A 1 /A 3 ) before GI or at the start of reperfusion or both before ischemia and at the start of reperfusion. All results are shown as the mean Ϯ SE for n ϭ 6 hearts for each group. *Significant differences at P Ͻ 0.05 vs. APC. Fig. 7 . LVPDP (in mmHg) during equilibrium, GI (30-to 60-min perfusion), and reperfusion (60-to 180-min perfusion) in GI, APC, and APC hearts perfused separately with the A 3 adenosine receptor antagonists MRS-1191 and MRS-1220 before GI (MRS) or at the start of reperfusion (MRS-R). All results are shown as the mean Ϯ SE for n ϭ 6 hearts for each group. *Significant differences at P Ͻ 0.05 vs. APC.
investigation by this group (15), however, indicated that the A 3 receptor was poorly blocked by DPCPX, suggesting that the cardioprotective effects afforded by IPC may be mediated by the A 3 and not the A 1 receptor. This hypothesis was confirmed by this same group in a series of experiments wherein they showed that the adenosine receptor antagonist BWA-1433 (now GR-69019X) blocked the protection afforded by IPC (15) . GR-69019X (5 M) has been reported to selectively block both A 1 and A 3 receptors in the rabbit heart (24) .
In this report, we have used, separately, GR-69019X (5 M; A 1 /A 3 ) and MRS-1191/MRS-1220. MRS-1191/ MRS-1220 have been shown to be selective A 3 antagonists in the rat, human, and dog heart with ϳ100-fold A 3 selectivity in canine cardiomyocytes (7, 8, 14, 21) . In preliminary experiments, 100, 200, and 500 nmol/l concentrations of MRS-1191/MRS-1220 were investigated. Our results indicated that 100 nmol/l MRS-1191/MRS-1220 had no effect on APC cardioprotection; however, both 200 and 500 nmol/l MRS-1191/MRS-1220 significantly modulated APC cardioprotection. Similar results were obtained with 200 and 500 nmol concentrations (results not shown). No investigation of A 2 or A 2a receptors was undertaken. While we are unable to confirm the specificity of the adenosine receptor subtype(s) involved in the cardioprotection afforded by APC, our data would suggest that the adenosine receptors subtype is DPCPX insensitive.
At present, there is no direct evidence for the existence of adenosine A 3 receptors in the rabbit heart; however, there is sufficient indirect evidence to suggest that adenosine A 3 receptors are involved in the cardioprotection afforded by preconditioning in this model (1, 2, 8, 9, 10, 14, 15, 21, 24) . Armstrong and Ganote (1) have presented evidence for the role of A 3 adenosine receptors in the protection afforded by preconditioning in the isolated rabbit cardiomyocyte. The involvement of A 3 receptors in providing for cardioprotection in the rabbit heart is supported by Tracey et al. (24) and Auchampach et al. (2) , who have independently shown that the adenosine A 3 receptor agonist N 6 -(3-iodobenzyl)adenosine-5Ј-N-methyl-uronamide provides similar cardioprotection to that of IPC. Our results are in agreement with the findings of these investigators, in which we show that a bolus injection of adenosine significantly decreases infarct size providing similar cardioprotection as that observed with IPC. In this report, we have not used adenosine receptor agonists because the experimental design was to determine the mechanism of APC, not IPC, cardioprotection. In the absence of these experiments, we recognize that our results, as presented, using the adenosine receptor antagonists DPCPX (A 1 ) and GR-69019X (5 M; A 1 / A 3 ) are consistent with but not necessarily suggestive of the involvement of the adenosine A 3 receptor subtype in APC cardioprotection.
Jordan et al. (8) have shown that adenosine A 3 receptor activation attenuates neutrophil-mediated reperfusion injury. In this report, we have investigated the role of adenosine receptors in the isolated perfused Langendorff heart model, and, therefore, the effects of neutrophils and plasma-borne inflammatory components on infarct size were not be assessed. However, in earlier reports (16, 18) , we have shown that the beneficial effects of APC in reducing myocardial infarct size and enhancing postischemic functional recovery are preserved in the in situ blood-perfused heart model, providing similar cardioprotection after 30-min GI as that of cold blood cardioplegia. We speculate, based on our earlier reported results (16, 22, 23) and those of Jordan et al. (8) , that the cardioprotection afforded by APC in the in situ blood-perfused heart may occur, at least in part, via this mechanism.
Our results indicate that the omission of adenosine, supplied as a bolus in concert with IPC (Figs. 2 and 3 and Table 1 ), significantly decreases myocardial infarct size but does not provide for the significantly enhanced Fig. 8 . Infarct size after 30-min GI and 120-min reperfusion in GI, APC, and in APC hearts perfused separately with the following: 1) the A 1 receptor antagonist DPCPX before GI or at the start of reperfusion; 2) the adenosine receptor antagonist GR-69019X (A 1 /A 3 ) before GI or at the start of reperfusion or both before ischemia and at the start of reperfusion; 3) the A 3 adenosine receptor antagonists MRS-1191 and MRS-1220 before GI (MRS) or at the start of reperfusion (MRS-R); and 4) the nonselective adenosine receptor antagonist SPT (A 1 /A 2 /A 3 ) before GI or at the start of reperfusion. All results are shown as the mean Ϯ SE for n ϭ 6-8 hearts for each group. *Significant differences at P Ͻ 0.05 vs. APC. ¶Signif-icant differences at P Ͻ 0.05 vs. DPCPX and DPCPX-R. §Significant differences at P Ͻ 0.05 vs. GR-69019X-R, MRS-R, and SPT-R.
cardioprotection afforded by APC [significantly decreased infarct size and significantly enhanced postischemic functional recovery (P Ͻ 0.05 vs. ADO, IPC)], in agreement with our previous reports (16-18, 22, 23, 25) . Specifically, our data suggest that APC-enhanced cardioprotection is provided in two stages. First, APC significantly enhanced infarct size reduction (P Ͻ 0.05 vs. IPC) requires the combined actions of both a bolus injection of adenosine coincident with IPC to allow for adenosine receptor activation (DPCPX insensitive) before ischemia. The individual actions (IPC or ADO) or the separation of the actions of IPC and adenosine (IPCϩADO) failed to enhance infarct size beyond that afforded by the endogenous protection of IPC or adenosine alone and did not provide for enhanced postischemic functional recovery. Infarct size in APC hearts receiving SPT, GR-69019X, or MRS was not significantly different from that observed in GI hearts, further suggesting that APC-enhanced infarct size reduction is primarily modulated by the combined actions of both a bolus injection of adenosine coincident with IPC acting synergistically on adenosine receptors (DPCPX insensitive) before ischemia with limited infarct protection being conferred during reperfusion. Support for this hypothesis is found in the examination of infarct size in APC hearts in which SPT, GR-69019X, or MRS was administered before ischemia compared with APC hearts in which SPT, GR-69019X, or MRS was administered at the start of reperfusion (Fig. 8) . Infarct size was significantly increased (P Ͻ 0.05) in APC hearts in which SPT, GR-69019X, or MRS was administered before ischemia compared with APC hearts in which SPT, GR-69019X, or MRS was administered at the start of reperfusion (Fig. 8) . No significant differences in infarct size vs. GI hearts were observed in APC hearts in which SPT, GR-69019X, or MRS was administered before ischemia (Fig. 8) .
Second, our results indicate that APC significantly enhanced postischemic functional recovery (P Ͻ 0.05 vs. IPC, ADO, and IPCϩADO) requires the combined actions of both a bolus injection of adenosine coincident with IPC to allow for adenosine receptor activation (DPCPX insensitive) before ischemia and during reperfusion. No enhanced postischemic functional recovery was observed with IPCϩADO or with IPC or ADO (Fig. 2) . These data suggest that adenosine receptor activation, by IPC or adenosine before ischemia or the combination of IPC during ischemia and adenosine during reperfusion, is not sufficient to enhance postischemic functional recovery. Further support for this hypothesis comes from our results in which APC hearts were administered the nonselective adenosine receptor antagonist SPT. Our results show that infarct size was significantly increased (P Ͻ 0.05 vs. APC, NS vs. GI; Fig. 8 ) and postischemic functional recovery was significantly decreased (P Ͻ 0.05 vs. APC, NS vs. GI) in APC hearts in which SPT was administered before ischemia ( Fig. 4 and Table 2 ). In APC hearts in which SPT was administered at the start of reperfusion, APC-enhanced postischemic functional recovery was significantly decreased (P Ͻ 0.05 vs. APC, NS vs. GI; Fig. 4 and Table 2 ), but APC myocardial infarct size reduction was only compromised (Fig. 8) .
In total, these results and the results of our previous investigation (23) suggest that APC-enhanced infarct size reduction is modulated by the combined actions of both a bolus injection of adenosine coincident with IPC acting on mechanisms that include adenosine receptors (DPCPX insensitive) and K ATP channels primarily during ischemia, whereas APC-enhanced postischemic functional recovery is modulated by the combined actions of both a bolus injection of adenosine coincident with IPC acting on mechanisms that include adenosine receptors (DPCPX insensitive) and K ATP channels during both ischemia and reperfusion.
